The growth of Viagra and its impact on the medicinal landscape presents a complicated question for shareholders. While the first sales statistics were impressive, the intellectual property has lapsed, leading to a flood of off-brand alternatives that are chipping away at revenue. Furthermore, the sector is facing issues related to population trends